Role of anti-TNF-α therapy in fat graft preservation.
Yang M., Zhang F., Sailes FC., Zhang EW., Lin S., Das SK.
Animal Study, published in Ann Plast Surg (2012) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Ann Plast Surg (2012)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 21629060
- DOI
- 10.1097/SAP.0b013e31821deb1b
Abstract (original English)
In this study, we evaluated the role of antitumor necrosis factor-alpha (TNF-α) therapy in the decrease of adipocyte apoptosis and weight preservation of fat grafts in the rat model. A total of 64 rats were randomly divided into 2 groups, with 32 rats in each group. Autologous fat tissue was grafted subcutaneously on the back of each rat. For the experimental group, antirat TNF-α monoclonal antibody was injected into the fat grafts during operation. No treatment was given to the tissue in the control group. Eight rats in each group were killed respectively, at days 7, 14, 30, and 60 postoperatively and sampled for assessments of weight preservation, gene expression of TNF-α, histology, and adipocyte apoptosis. There were no significant differences in the weight of fat tissues between the control group and the experimental group at days 7, 14, and 30 postoperatively (P > 0.05). However, the preservation ratio of the tissue was 65.36% ± 14.98% in the antirat TNF-α antibody-treated group when compared with the weight at transplantation, which was significantly higher than the control group (44.63% ± 10.39%) 60 days after the operation (P < 0.05). The numbers of apoptotic cells in the control group were 15.6 ± 3.17, 24.6 ± 4.34, 22.8 ± 2.42, and 27 ± 3.83 per field at different postoperative intervals. However, the numbers of apoptotic cells in the tissues treated with TNF-α antibo
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.